Comparison of [sup 131]I- and [sup 90]Y-labeled monoclonal antibody 17-1A for treatment of human colon cancer xenografts

Journal Article · Mon Mar 15 00:00:00 EST 1993 · International Journal of Radiation Oncology, Biology and Physics; (United States)

DOI:https://doi.org/10.1016/0360-3016(93)90009-K· OSTI ID:6756042

Buchsbaum, D J ^[1]; Lawrence, T S; Roberson, P L; Heidorn, D B; Ten Haken, R K ^[2]; Steplewski, Z ^[3]

---

1. Univ. of Alabama, Birmingham, AL (United States)
2. Univ. of Michigan, Ann Arbor, MI (United States)
3. Wistar Institute, Philadelphia, PA (United States)

The choice of radionuclide remains an important question in clinical radioimmunotherapy. Therefore, a study was initiated, using an in vivo model system, to assess the relative merits of [sup 131]I- and [sup 90]Y-labeled 17-1A monoclonal antibody as therapeutic agents in the treatment of colon cancer. [sup 131]I- and [sup 90]Y-labeled 17-1A were assessed in animal therapy trials using athymic nude mice bearing LS174T human colon cancer xenografts. [sup 131]I-labeled 17-1A decreased tumor growth in a dose-dependent fashion without lethality. In contrast, the doses of [sup 90]Y-labeled 17-1A which were required to produce a significant increase in tumor doubling time also caused marked toxicity. Although similar tumor growth inhibition was produced by 250 [mu]Ci [sup 90]Y- and 150 [mu]Ci [sup 131]I-labeled 17-1A, Medical Internal Radiation Dose calculations based on biodistribution data estimated that the dose delivered by [sup 90]Y was greater than that delivered by [sup 131]I. To investigate this discrepancy, 3-dimensional dose distributions within LS174T tumors were assessed using autoradiography and 3-dimensional calculational techniques. It was found that a greater fraction of the dose was deposited in the tumor after treatment with [sup 131]I- compared to [sup 90]Y-labeled 17-1A. When the Medical Internal Radiation Dose calculations were adjusted using the 3-dimensional dose distributions, 250 [mu]Ci of [sup 90]Y- and 150 [mu]Ci of [sup 131]I-labeled 17-1A were found to deliver similar tumor doses. These studies suggest that [sup 131]I-labeled 17-1A is superior to [sup 90]Y-labeled 17-1A, since [sup 131]I-labeled antibody produced less hematological and animal toxicity and was more effective at inhibiting LS174T tumor growth than [sup 90]Y-labeled antibody across the range of radionuclide doses tested. Furthermore, they suggest that it will be necessary to perform 3-dimensional dose calculations. 33 refs., 7 figs., 4 tabs.

• OSTI ID: 6756042
• Journal Information: International Journal of Radiation Oncology, Biology and Physics; (United States), Vol. 25:4; ISSN 0360-3016
• Country of Publication: United States
• Language: English

Related Subjects

63 RADIATION, THERMAL, AND OTHER ENVIRON. POLLUTANT EFFECTS ON LIVING ORGS. AND BIOL. MAT.
61 RADIATION PROTECTION AND DOSIMETRY
62 RADIOLOGY AND NUCLEAR MEDICINE
IODINE 131
TISSUE DISTRIBUTION
TOXICITY
RADIATION DOSE DISTRIBUTIONS
THREE-DIMENSIONAL CALCULATIONS
YTTRIUM 90
COMPARATIVE EVALUATIONS
BETA DECAY RADIOISOTOPES
BETA-MINUS DECAY RADIOISOTOPES
DAYS LIVING RADIOISOTOPES
DISTRIBUTION
EVALUATION
HOURS LIVING RADIOISOTOPES
INTERMEDIATE MASS NUCLEI
IODINE ISOTOPES
ISOMERIC TRANSITION ISOTOPES
ISOTOPES
NUCLEI
ODD-EVEN NUCLEI
ODD-ODD NUCLEI
RADIOISOTOPES
YTTRIUM ISOTOPES
560160* - Radionuclide Effects
Kinetics
& Toxicology
560101 - Biomedical Sciences
Applied Studies- Radiation Effects- Dosimetry & Monitoring- (1992-)
550604 - Medicine- Unsealed Radionuclides in Therapy- (1980-)